BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: Using guidelines to make rational treatment choices

Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

The success of the BCR-ABL tyrosine kinase inhibitor (TKI) imatinib in improving prognosis in chronic myeloid leukemia (CML) has led to its wide use as first-line therapy at a standard dose of 400 mg daily. As more patients have undergone therapy, the development of molecular and clinical resistance to imatinib has raised further therapeutic challenges. The 2 main approaches to overcoming resistance are imatinib dose escalation and the use of alternative more potent TKIs, such as dasatinib or nilotinib. The phase II SRC/ABL Tyrosine Kinase Inhibition Activity Research Trials (START) of dasatinib have established dasatinib as potent and effective in overcoming imatinib resistance or intolerance in all phases of CML. The most recent treatment guidelines by the National Comprehensive Cancer Network now contain recommendations for using dasatinib in this setting. The issue of when to change from imatinib to an alternative agent in preference to imatinib dose escalation is keenly debated, particularly as new clinical evidence emerges, which highlights the importance of achieving early cytogenetic and molecular responses for a good long-term outcome. Identifying patients in whom a change to dasatinib or nilotinib is more appropriate than imatinib dose escalation is therefore important.

Original languageEnglish (US)
Pages (from-to)S37-S42
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume6
Issue numberSUPPL. 2
StatePublished - Jun 30 2008
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Guidelines
Therapeutics
Leukemia, Myeloid, Chronic Phase
Imatinib Mesylate
Cytogenetics
Dasatinib
Research
Neoplasms

Keywords

  • CML
  • Dasatinib
  • Guidelines
  • Imatinib
  • Nilotinib
  • Resistance

ASJC Scopus subject areas

  • Oncology

Cite this

BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia : Using guidelines to make rational treatment choices. / Kantarjian, Hagop; Cortes, Jorge.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 6, No. SUPPL. 2, 30.06.2008, p. S37-S42.

Research output: Contribution to journalReview article

@article{cd6c9783fe8b4c13ac68ee34206884fd,
title = "BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: Using guidelines to make rational treatment choices",
abstract = "The success of the BCR-ABL tyrosine kinase inhibitor (TKI) imatinib in improving prognosis in chronic myeloid leukemia (CML) has led to its wide use as first-line therapy at a standard dose of 400 mg daily. As more patients have undergone therapy, the development of molecular and clinical resistance to imatinib has raised further therapeutic challenges. The 2 main approaches to overcoming resistance are imatinib dose escalation and the use of alternative more potent TKIs, such as dasatinib or nilotinib. The phase II SRC/ABL Tyrosine Kinase Inhibition Activity Research Trials (START) of dasatinib have established dasatinib as potent and effective in overcoming imatinib resistance or intolerance in all phases of CML. The most recent treatment guidelines by the National Comprehensive Cancer Network now contain recommendations for using dasatinib in this setting. The issue of when to change from imatinib to an alternative agent in preference to imatinib dose escalation is keenly debated, particularly as new clinical evidence emerges, which highlights the importance of achieving early cytogenetic and molecular responses for a good long-term outcome. Identifying patients in whom a change to dasatinib or nilotinib is more appropriate than imatinib dose escalation is therefore important.",
keywords = "CML, Dasatinib, Guidelines, Imatinib, Nilotinib, Resistance",
author = "Hagop Kantarjian and Jorge Cortes",
year = "2008",
month = "6",
day = "30",
language = "English (US)",
volume = "6",
pages = "S37--S42",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "SUPPL. 2",

}

TY - JOUR

T1 - BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia

T2 - Using guidelines to make rational treatment choices

AU - Kantarjian, Hagop

AU - Cortes, Jorge

PY - 2008/6/30

Y1 - 2008/6/30

N2 - The success of the BCR-ABL tyrosine kinase inhibitor (TKI) imatinib in improving prognosis in chronic myeloid leukemia (CML) has led to its wide use as first-line therapy at a standard dose of 400 mg daily. As more patients have undergone therapy, the development of molecular and clinical resistance to imatinib has raised further therapeutic challenges. The 2 main approaches to overcoming resistance are imatinib dose escalation and the use of alternative more potent TKIs, such as dasatinib or nilotinib. The phase II SRC/ABL Tyrosine Kinase Inhibition Activity Research Trials (START) of dasatinib have established dasatinib as potent and effective in overcoming imatinib resistance or intolerance in all phases of CML. The most recent treatment guidelines by the National Comprehensive Cancer Network now contain recommendations for using dasatinib in this setting. The issue of when to change from imatinib to an alternative agent in preference to imatinib dose escalation is keenly debated, particularly as new clinical evidence emerges, which highlights the importance of achieving early cytogenetic and molecular responses for a good long-term outcome. Identifying patients in whom a change to dasatinib or nilotinib is more appropriate than imatinib dose escalation is therefore important.

AB - The success of the BCR-ABL tyrosine kinase inhibitor (TKI) imatinib in improving prognosis in chronic myeloid leukemia (CML) has led to its wide use as first-line therapy at a standard dose of 400 mg daily. As more patients have undergone therapy, the development of molecular and clinical resistance to imatinib has raised further therapeutic challenges. The 2 main approaches to overcoming resistance are imatinib dose escalation and the use of alternative more potent TKIs, such as dasatinib or nilotinib. The phase II SRC/ABL Tyrosine Kinase Inhibition Activity Research Trials (START) of dasatinib have established dasatinib as potent and effective in overcoming imatinib resistance or intolerance in all phases of CML. The most recent treatment guidelines by the National Comprehensive Cancer Network now contain recommendations for using dasatinib in this setting. The issue of when to change from imatinib to an alternative agent in preference to imatinib dose escalation is keenly debated, particularly as new clinical evidence emerges, which highlights the importance of achieving early cytogenetic and molecular responses for a good long-term outcome. Identifying patients in whom a change to dasatinib or nilotinib is more appropriate than imatinib dose escalation is therefore important.

KW - CML

KW - Dasatinib

KW - Guidelines

KW - Imatinib

KW - Nilotinib

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=45749149540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749149540&partnerID=8YFLogxK

M3 - Review article

C2 - 18397680

AN - SCOPUS:45749149540

VL - 6

SP - S37-S42

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - SUPPL. 2

ER -